Recently, the results of a new ivermectin study out of Columbia were reported in the medical journal JAMA. Led by Eduardo […]
A recent study sponsored by Massachusetts General Hospital in collaboration with the National Multiple Sclerosis Society and Pillsy Inc. was […]
AstraZeneca reported that its Phase 3 KESTREL trial of Imfinzi (durvalumab) failed to meet the primary endpoint of improving overall […]
Galapagos and Gilead have halted the phase 3 ISABELA program, consisting of two studies evaluating ziritaxestat in patients with idiopathic […]
The South African government, via South Africa Health Minister Dr. Zweli Mkhize, declared a temporary hold on the AstraZeneca (Oxford) […]
Amgen released its financial results for the fourth quarter and full year 2020. Among the key results, Amgen disclosed that […]
Concert Pharmaceuticals reported that its Phase 2 trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did […]
Biogen announced in its annual results and earnings presentation that its Phase II SPARK study of cinpanemab (BIIB054), under development for Parkinson’s […]
A Kuwait-based clinical trial sponsored by Indian generic drug producer Dr. Reddy’s Laboratory was recently terminated as the resulting data […]
BioHaven Pharmaceuticals announced the outcome from a focused analysis of the topline co-primary and key secondary data from its Phase […]
